<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>GUFICBIO on Financial Report Insights</title>
    <link>https://reports.muthu.co/tags/guficbio/</link>
    <description>Recent content in GUFICBIO on Financial Report Insights</description>
    <generator>Hugo</generator>
    <language>en-us</language>
    <lastBuildDate>Fri, 21 Feb 2025 13:55:34 +0000</lastBuildDate>
    <atom:link href="https://reports.muthu.co/tags/guficbio/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Gufic BioSciences Ltd - Feb 2025 Earnings Call Transcript Analysis</title>
      <link>https://reports.muthu.co/posts/gufic-biosciences-ltd---feb-2025-earnings-call-transcript-analysis/</link>
      <pubDate>Fri, 21 Feb 2025 13:55:34 +0000</pubDate>
      <guid>https://reports.muthu.co/posts/gufic-biosciences-ltd---feb-2025-earnings-call-transcript-analysis/</guid>
      <description>&lt;h2 class=&#34;heading&#34; id=&#34;earnings-call-transcript-analysis-report&#34;&gt;&#xA;  Earnings Call Transcript Analysis Report&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#earnings-call-transcript-analysis-report&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;h2 class=&#34;heading&#34; id=&#34;financial-performance&#34;&gt;&#xA;  Financial Performance&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#financial-performance&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;key-financial-metrics-q3-fy25-vs-q3-fy24&#34;&gt;&#xA;  Key Financial Metrics (Q3 FY25 vs Q3 FY24)&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#key-financial-metrics-q3-fy25-vs-q3-fy24&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Total Revenue from Operations:&lt;/strong&gt; INR 207.8 crores (up from INR 201.8 crores).&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Quote (CFO): &amp;ldquo;The total revenue for the operation for the financial year &amp;lsquo;24- &amp;lsquo;25 in Q3 is INR 207.8 crores compared to Q3 of financial year &amp;lsquo;23- &amp;lsquo;24 of INR 201.8 crores.&amp;rdquo;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;EBITDA:&lt;/strong&gt; INR 35.8 crores (down from INR 36.9 crores).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;EBITDA Margin:&lt;/strong&gt; 17.23% (down from 18.29%).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Profit Before Tax (PBT):&lt;/strong&gt; INR 26.3 crores (down from INR 29.6 crores).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;PBT Margin:&lt;/strong&gt; 12.66% (down from 14.67%).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Profit After Tax (PAT):&lt;/strong&gt; INR 19.4 crores (down from INR 22.3 crores).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;PAT Margin:&lt;/strong&gt; 9.34% (down from 11.05%).&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;key-financial-metrics-9m-fy25-vs-9m-fy24&#34;&gt;&#xA;  Key Financial Metrics (9M FY25 vs 9M FY24)&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#key-financial-metrics-9m-fy25-vs-9m-fy24&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Total Revenue from Operations:&lt;/strong&gt; INR 614.8 crores (slightly down from INR 616.7 crores).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;EBITDA:&lt;/strong&gt; INR 111.6 crores (slightly down from INR 112.9 crores).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;EBITDA Margin:&lt;/strong&gt; 18.15% (slightly down from 18.31%).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Profit Before Tax (PBT):&lt;/strong&gt; INR 83.6 crores (down from INR 88.6 crores).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;PBT Margin:&lt;/strong&gt; 13.60% (down from 14.37%).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Profit After Tax (PAT):&lt;/strong&gt; INR 61.9 crores (down from INR 66.1 crores).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;PAT Margin:&lt;/strong&gt; 10.07% (down from 10.72%).&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;revised-guidance-or-forecasts&#34;&gt;&#xA;  Revised Guidance or Forecasts&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#revised-guidance-or-forecasts&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Indore facility expected to generate INR 6 crores in Q3 FY25, with Q4 FY25 revenue projected at INR 20 crores (CFO) or 2-3x of Q3 (CEO).&lt;/li&gt;&#xA;&lt;li&gt;Indore facility FY26 revenue forecast: &amp;ldquo;minimum INR150 crores additional revenue&amp;rdquo; (CFO).&lt;/li&gt;&#xA;&lt;li&gt;Margin pressure expected in the near term due to Indore start-up costs, with improvement anticipated post-FY26.&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Quote (CFO): &amp;ldquo;after &amp;lsquo;26, when the capacity utilization of Indore will be picked up, I think that the EBITDA margin and PAT margin is going to improve after &amp;lsquo;26 onwards.&amp;rdquo;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;areas-of-growth-or-decline&#34;&gt;&#xA;  Areas of Growth or Decline&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#areas-of-growth-or-decline&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Revenue showed slight YoY growth for Q3 but was flat for 9M.&lt;/li&gt;&#xA;&lt;li&gt;EBITDA, PBT, and PAT declined both YoY for Q3 and for the 9M period, with corresponding margin compression.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&#xA;&#xA;&#xA;&lt;div class=&#34;button-container&#34;&gt;    &#xA;    &lt;a href=&#34;http://gufic.com/Notice/Written%20Transcript%2017022025.pdf&#34; target=&#34;_blank&#34; class=&#34;report-button&#34;&gt;&#xA;      &lt;i class=&#34;fas fa-file-pdf&#34;&gt;&lt;/i&gt; Download Transcript&#xA;    &lt;/a&gt;&#xA;&lt;/div&gt;</description>
    </item>
    <item>
      <title>Gufic BioSciences Ltd:Annual Report 2023-24 Analysis</title>
      <link>https://reports.muthu.co/posts/gufic-biosciences-ltdannual-report-2023-24-analysis/</link>
      <pubDate>Sat, 31 Aug 2024 19:07:18 +0000</pubDate>
      <guid>https://reports.muthu.co/posts/gufic-biosciences-ltdannual-report-2023-24-analysis/</guid>
      <description>&lt;h2 class=&#34;heading&#34; id=&#34;gufic-biosciences-ltd-a-comprehensive-overview&#34;&gt;&#xA;  Gufic Biosciences Ltd.: A Comprehensive Overview&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#gufic-biosciences-ltd-a-comprehensive-overview&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;about-the-company&#34;&gt;&#xA;  About the Company&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#about-the-company&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;h4 class=&#34;heading&#34; id=&#34;year-of-establishment-and-founding-history&#34;&gt;&#xA;  Year of Establishment and Founding History&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#year-of-establishment-and-founding-history&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h4&gt;&#xA;&lt;p&gt;Gufic Biosciences Ltd. was established in &lt;strong&gt;1984&lt;/strong&gt; by Mr. Jayesh Choksi. The company started as a pharmaceutical manufacturing and marketing company.&lt;/p&gt;&#xA;&lt;h4 class=&#34;heading&#34; id=&#34;headquarters-location-and-global-presence&#34;&gt;&#xA;  Headquarters Location and Global Presence&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#headquarters-location-and-global-presence&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h4&gt;&#xA;&lt;p&gt;The company&amp;rsquo;s headquarters is located in &lt;strong&gt;Mumbai, India&lt;/strong&gt;. Gufic Biosciences has a global presence, exporting to various countries in &lt;strong&gt;Asia, Africa, and Latin America.&lt;/strong&gt;&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
